Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports 2017

Analyst Reports 2017
December 13th 2017

EDISON - Encouraging LAG-3 combo data at SITC

November 29th 2017

Maxim - IMP321 + Keytruda: Positive Data in Melanoma to be Presented at SITC

November 16th 2017

Maxim - IMP321 (LAG-3Ig) Heating up the T cell Response for Keytruda in Melanoma - New Data To Be Presented at-SITC

October 11th 2017

Edison - Support for anti-LAG-3 and APC-activator combos

September 7th 2017

Edison - Support for Anti-Lag-3 and APC-Activators Combos

August 2nd 2017

Maxim Research - Understanding LAG-3 Function in Controlling T Cells- Grant Funding Awarded to Prima

July 2nd 2017

Maxim PBMD Report - Coming to the Next Checkpoint: LAG-3 and Prima has the Right Partner in Novartis

June 2nd 2017

Edison - Preliminary LAG-3 combo data in breast cancer

March 2nd 2017

Edison - Initial LAG-3 combo data presented

February 2nd 2017

H.C. Wainwright - Looking Ahead to a Catalyst-Rich 2017; Reiterate Buy

February 2nd 2017

Edison - Prima BioMed - AIPAC Phase IIb starts randomized component

January 2nd 2017

FRB & Co. - Green Shoots from Broad Clinical Progress Are Emerging

January 2nd 2017

Research Note – Ongoing strong data support LAG-3 pipeline